Lilly and Novo say GLP-1 drugs lower biological age by about two to three years on aging clocks

MIT Technology Review reported on 6 October 2026 that Eli Lilly and Novo Nordisk found overweight or diabetic patients taking their GLP-1 drugs had a lower biological age than those on placebo, as measured by molecular 'aging clocks'. The difference varied widely depending on the clock used and the organ tested. Novo's Nikolaj Roed put it at around two to three years overall, and aging-clock researcher Steve Horvath called a two-year effect 'pretty strong'.

What it means If drugmakers start citing aging-clock results, biological age becomes a marketed endpoint, and how much the clocks disagree with each other becomes a practical question.